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Abstract
A large burden of undiagnosed hepatitis virus cases remains globally. Despite the 257 million people living with chronic
hepatitis B virus infection, and 71 million with chronic viraemic HCV infection, most people with hepatitis remain unaware
of their infection. Advances in rapid detection technology have created new opportunities for enhancing access to
testing and care, as well as monitoring of treatment. This article examines a range of other technological innovations
that can be leveraged to provide more affordable and simplified approaches to testing for HBV and HCV infection and
monitoring of treatment response. These include improved access to testing through alternative sampling methods
(use of dried blood spots, oral fluids, self-testing) and combination rapid diagnostic tests for detection of HIV, HBV and
HCV infection; more affordable options for confirmation of virological infection (HBV DNA and HCV RNA) such as point-of-
care molecular assays, HCV core antigen and multi-disease polyvalent molecular platforms that make use of existing
centralised laboratory based or decentralised TB and HIV instrumentation for viral hepatitis testing; and finally health
system improvements such as integration of laboratory services for procurement and sample transportation and
enhanced data connectivity to support quality assurance and supply chain management.
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Background
It is estimated that in 2015, 257 million people were
living with chronic hepatitis B virus (HBV) infection and
71 million with chronic viraemic hepatitis C (HCV) in-
fection [1, 2]. The African and Western Pacific regions
account for 68% of those infected with HBV, while the
European and Eastern Mediterranean regions are more
affected by HCV. Untreated HBV and HCV infection
can lead to life-threatening complications of cirrhosis
and hepatocellular carcinoma accounting for 720,000
and 470, 000 annual deaths, respectively [1, 3]. Mortality
from viral hepatitis has also increased 22% since 2000
and unless diagnosed and treated, the number of deaths
due to viral hepatitis will continue to increase [4]. Yet,
the majority of these infections remain undiagnosed
globally. In 2015, only 9% of HBV infected persons
and 20% of HCV were tested and aware of their diag-
nosis [1]. The 2016 World Health Organization
(WHO) global health sector strategy on viral hepatitis
has now set ambitious targets to eliminate viral hepa-
titis as a public health threat by 2030 (defined as a
65% reduction in mortality and a 90% reduction in
incidence compared with the 2015 baseline) [5].
In this article we review existing technologies (sero-
logical and virological) for hepatitis testing and recom-
mendations for testing from the 2017 WHO Guidelines
on Hepatitis B and C testing [6]. We identify remaining
challenges and explore technological advances and inno-
vations that can help countries address these challenges
and reach the WHO targets. These include improved ac-
cess to testing through alternative sampling methods
(use of dried blood spots, oral fluids, self-testing);
more affordable options for confirmation of virological
infection (HBV DNA and HCV RNA) that include
point-of-care molecular assays, HCV core antigen and
multi-disease (HIV/TB/HCV/HBV) polyvalent molecular
platforms that make use of existing centralised laboratory
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based or decentralised instrumentation for viral hepatitis
testing; and finally health system improvements such as
integration of laboratory services for procurement and
sample transportation and enhanced data connectivity to
support quality assurance and supply chain management.
Current testing technologies
Serological testing
Serological assays are typically used as the first line of
the testing strategy to screen for exposure to a virus and
detect the host immune response (antibodies to HCV)
or a viral antigen (HBsAg, HCVcAg). Hepatitis sero-
logical assays are based on the immunoassay principle,
and are available in the form of rapid diagnostic tests
(RDTs) or laboratory-based enzyme immunoassays (EIAs),
chemoluminescence immunoassays (CLIAs) and electro-
chemoluminescence immunoassays (ECLs). These latter
assays offer excellent precision and reliability, high-speed
throughput, random access, and the technical simplicity
of full automation for high-volume clinical laboratories.
Rapid diagnostic tests (RDTs) provide improved access to
testing as they are simple, low cost, and can use serum
and plasma, as well as capillary whole blood collected with
a finger prick. They can also be performed by trained lay
providers or health-care workers in resource-limited set-
tings without the need for specialized equipment or
venepuncture. Current costs for EIA assays range from 1
to 9 USD per test and RDTs range from 0.5 – 7USD.
Virological testing
Nucleic acid testing (NAT) technologies are highly ac-
curate in detecting the presence of viral nucleic acid
(DNA or RNA), and are used to confirm either the pres-
ence or absence (qualitative) or level (quantitative) of
viraemia to guide treatment decisions and monitor treat-
ment response, and confirm either virological cure (HCV)
or effective suppression (HBV). Hepatitis NAT assays are
traditionally performed as laboratory based assays re-
quiring highly trained staff and their current costs
which range from 30 to 120 USD are unaffordable for
majority of patients in low-resource settings.
Recommended algorithms for hepatitis testing in
2017 WHO testing guidelines [6]
Overall, the guidelines recommend the use of a single
quality-assured serological in vitro diagnostic test
(i.e.either a laboratory-based immunoassay [EIA or
chemiluminiscence immunoassay] or RDT) to detect
HBsAg and HCV antibody that meet minimum per-
formance standards [6]. The use of HBV DNA NAT
following a reactive HBsAg serological test result has
been recommended to help further guide treatment
and monitoring where available [7]. Following a reactive
HCV antibody serological test result, the 2017 WHO
Guidelines Development Group made a strong recom-
mendation for the use of either qualitative or quantitative
NAT for diagnosis of HCV infection, with a qualitative
assay being considered sufficient now in the era of highly
effective direct acting antiviral regimens [8]. A systematic
review was conducted to determine the accuracy of quali-
tative versus quantitative NAT methods for HCV RNA for
detection (and/or) quantification to confirm viraemic
HCV infection. The lower limit of detection was in the 10
to 15 IU/mL range for most qualitative assays, and 600–
1100 IU/mL for quantitative assays. Table 1 summarises
the included studies - the sensitivity of HCV viral quantita-
tive assays was 87–100% compared to qualitative assays
and most assays were able to detect all genotypes [9–12].
Since the review, six new quantitative molecular technology
platforms have become available with linear ranges of quan-
titation between 12 to 108 IU/mL and lower limits of detec-
tion of 15 IU/mL, which is comparable to qualitative
assays. However, quantitative assays still provide a reprodu-
cible method to detect and quantify HCV RNA in plasma
or serum, especially in the context of research studies. It
was also observed that most qualitative or quantitative
NAT assays as well as core Ag will capture the majority of
viraemic infections, since 95% of those with chronic infec-
tion have a viral load > 10,000 IU/mL [13].
In settings where NAT for confirmation of HCV viraemic
infection is not available, the WHO guidelines recom-
mended that HCV core antigen with comparable clinical
sensitivity to NAT technologies could be considered as a
potentially more affordable alternative [6]. This was sup-
ported by a systematic review of the diagnostic accuracy of
seven commercial HCVcAg assays compared to NAT as-
says. Certain commercial HCVcAg assays had a high sensi-
tivity (up to 93.4%) and a high specificity (> 98%) [13].
Technological advances and innovations to
improve access to testing
Understanding the major reasons for the current low
rate of hepatitis testing in resource limited settings is
critical to inform optimal positioning of new technolo-
gies to expand access to testing and treatment [14]. In
addition to the current limited number of clinics and
settings offering viral hepatitis testing and low demand
from general population due to the lack of awareness on
viral hepatitis, the costs of assays to confirm virological
infection remain high and unaffordable for many hepa-
titis control programmes in low and middle income
countries [15]. In recent years, diagnostic innovations in
many areas of health have been driven by well-funded
high priority diseases such as HIV and tuberculosis,
global health emergencies and epidemic preparedness
and information technology and data connectivity [16].
Examples of these innovations include HIV self-testing,
mobile health applications, integration and co-location
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of HIV/AIDS tuberculosis and drug treatment services
[17–20]. Table 2 summarizes a range of strategies and
technological innovations that can be leveraged to im-
prove access to HBV and HCV testing and treatment
monitoring.
Simplification of testing algorithms to improve uptake
and reduce costs
The WHO Guidelines on Hepatitis B and C Testing
(2017) provide the basis and rationale for simplification
of testing algorithms to increase affordability and so in
turn uptake of testing [6]. First, the availability now of
pan-genotypic DAA drugs eliminates the need for costly
genotyping which is largely unavailable in resource
limited settings. Second, the high rates of cure with
DAA regimens means that only a single test of cure is
required and no on-treatment monitoring. Table 3
summarises this evolving simplification in testing
strategies for HCV infection, and associated potential
cost reductions. In the future, considerations for one-
step diagnostic approaches using either HCV core anti-
gen or HCV RNA assays in high-prevalence popula-
tions (ie. > 70% seroprevalence), such as persons who
inject drugs or in prisons may also offer further simplifica-
tion, reducing loss-to-follow-up and enabling same-day
treatment initiation.
New sampling approaches
Dried blood spots for serology and virology to promote
testing uptake and linkage to care
Dried blood spot (DBS) specimens have been used suc-
cessfully to expand access to HIV testing due to the low
cost, relative ease of specimen collection with avoidance
of venepuncture, easier handling that does not require
high skill, transportation with lower biohazard risk, and
easier storage options [21]. The 2017 WHO Guidelines
Development Group recognized the benefits of DBS and
in particular their potential to facilitate greater access to
testing and recommended considering DBS for both
serological and NAT HBV and HCV technologies [6].
Table 1 Diagnostic performance of qualitative vs quantitative HCV RNA NAT in five studies included in 2017 systematic review
Author, year and country Sample type & number Study population Diagnostic test
(Quantitative)
Reference test
(Qualitative)
Sensitivity Specificity
Lee et al., 2000,
USA [9]
Serum
N = 51
Patients at risk of HCV
infection
Roche AMPLICOR HCV
test, version 2.0
Roche COBAS AMPLICOR
TM HCV Test v2.0
100% at 50 IU/mL;
91% at 25 IU/mL*
Yu et al., 2000,
Taiwan [10]
Serum
N = 215
Patients with chronic
HCV
Bayer bDNA-2
Quantiplex HCV test
Roche COBAS AMPLICOR
TM HCV Test v2.0
95% –
Sabato et al., 2007,
USA [11]
Plasma
N = 76
Patients with
HCV infection
Bayer Versant HCV
genotype assay
Roche COBAS AMPLICOR
TM HCV Test v1.0
100% 100%
Vermehren et al., 2008,
Germany [12]
Serum
N = 65
Patients with HCV Bayer Versant HCV
genotype assay
Abbott Real-Time Assay 87% –
*CAP/CTM Roche Cobas Ampliprep/ Cobas Taqman HCV assay, IU International Units
Table 2 Summary of innovative technologies to provide more affordable and simplified HBV and HCV testing and treatment
monitoring
Area of Innovation Technology or strategy Primary testing
target
Potential future
testing target
Potential impact
1. Simplification of
algorithms
• Elimination of need for genotyping
with access to pan-genotypic DAAs,
and only a single time point (SVR12)
for assessment of cure
HCV Reduce costs; Improve uptake
2. Sampling approaches • Dried blood spots (DBS)
• Oral fluid
• HCV
• HCV
Increase access and coverage,
reaching key and target populations
3. Innovative testing
approaches
• Self-testing
• Combo integrated multi-disease tests
• Integrated multidisease testing
platforms (centralised and decentralised)
• HCV
• HCV
• HCV
• HBV
• HBV
Increase awareness, reduce stigma;
Maximise programme synergies and
reduce costs. Improve access to
testing,
4. New technologies • Point-of-care (POC) NAT
• HCV core antigen test (as laboratory
based assay and in future as POC)
• HCV
• HCV
• HBV Increase access to confirmation of
viraemia
5. Health system
improvements
• Integrated testing and service
decentralization
• Data connectivity
• Sample chain and supply management
• HCV • HBV Improve timely receipt of results
and linkage to care; improve
supply chain management;
Optimize use of current infrastructure,
sample workflow
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Four systematic reviews and meta-analyses on the diag-
nostic accuracy and impact of using DBS specimens for
hepatitis B and C serological and NAT testing showed
generally high diagnostic accuracy and precision of DBS
specimens for both serology testing and NAT [22, 23].
DBS specimens were generally stable over time and
maintained good accuracy in conditions with higher
temperatures or humidity.
Current research priorities include the validation of
commercial assays, both serological and molecular, using
DBS, and to assess their performance in different popu-
lations and settings. The availability of DBS, both for ser-
ology testing and NAT, could allow a one-sampling
strategy where the same DBS card is initially used with
serology for screening and then reflex to NAT in those
samples that are antibody positive. This strategy, if
properly implemented, might result in major cost
savings and expansion of testing. The Foundation for
Innovative New Diagnostics (FIND), through a grant
from UNITAID, is supporting manufacturers with the
evaluation and optimization of both serology and
molecular assays using DBS specimens. These studies,
conducted initially in a reference laboratory and then in
the field, aim to accelerate the submission of DBS pro-
tocols for regulatory approval (i.e. European CE IVD or
WHO PQ) [24].
Testing using oral fluids
RDTs increase testing opportunities as their simplicity
and flexibility allows use of multiple specimen types (e.g.
venous, fingerstick blood, and oral fluid). In the field of
HIV, the use of oral HIV RDTs for community based or
home self-testing has increased access to testing for
those who are marginalised or reluctant to visit clinics
for testing due to stigma, and has been particularly suc-
cessful among men who have sex with men [25, 26]. It
would be anticipated that use of oral fluids for HBsAg
and HCV testing would also increase access to testing in
hard to reach populations including those in rural
settings.
For viral hepatitis, use of oral fluids is currently only
available with one quality approved HCV antibody RDT.
Lee and colleagues evaluated the performance of the
OraQuick® HCV Rapid Antibody Test in at-risk and
symptomatic patients comparing the diagnostic perform-
ance to venous blood, fingerstick capillary blood, serum
and plasma [9]. The overall sensitivities and specificities
were almost identical (sensitivity, 99.7–99.9% and speci-
ficity, 99.6–99.9%) for all five specimen types. The ob-
served sensitivity of the OraQuick test was slightly lower
for oral fluid at 98.1% though the upper CI (99.0%) was
equal to the lower CI for venous blood and fingerstick
blood. Most of the study subjects with false negative
OraQuick test results had serological and virological re-
sults consistent with resolved infection. Sensitivity for
anti-HCV in early seroconversion was virtually identical
between the HCV rapid test and EIA. The OraQuick®
HCV Rapid Antibody Test demonstrated clinical perform-
ance that was equivalent to current laboratory-based EIAs.
Major limitations to expanded use of oral testing are the
current high costs of the OraQuick assay [27].
Innovative testing approaches
Self-testing
Self-testing is currently an area of active research and
implementation in HIV to improve access and uptake
among specific populations, such as men who have sex
with men or persons who inject drugs [28]. Multiple
studies now show that HIV self–testing (HIVST) is ac-
ceptable among different high-risk populations who may
not otherwise have access to testing. Mokgatle and col-
leagues assessed the acceptability of HIVST among stu-
dents in two provinces in South Africa [29]. Overall,
87.1% and 75.6% of participants were willing to confirm
HIVST results at a local health facility. In Zimbabwe
and Malawi, Indravudh and colleagues found that
HIVST was highly acceptable to young people largely
because it empowers them to choose location and timing
of the test and control disclosure of results [30]. High
acceptability of self-testing for HIV status using an oral
fluid-based RDT was observed among pregnant women
in rural India [31]. In a survey among MSM in the UK,
the primary perceived benefit of HIVST was privacy and
confidentiality, with convenience cited as another benefit
among those who had difficulty accessing services [32].
Based on country commitments to date, at least 4 mil-
lion HIVST kits are expected to be procured by donor-
funded programmes from July 2017 to the end of 2018
[33]. It remains unclear whether self-testing might play a
similar role in promoting uptake of viral hepatitis testing
among high risk populations. A key difference between
HCV and HIV testing, is that the former still requires a
test of viraemia to confirm need for treatment, while for
HIV, the serological antibody test alone is sufficient.
Table 3 Simplifying testing algorithm and lowering the cost of monitoring treatment for HCV in the future
Screening for exposure Confirm viremia Guide treatment Treatment baseline/
monitoring
Post-treatment Cost of
testing
Current Testing scenarios EIA/RDT RNA qual RNA quant Genotyping Toxicity
RNA quant
RNA qual ~220–1100 USD
Future Testing scenarios EIA/RDT/Oral/DBS RNA qual/quant NA RNA qual/quant RNA qual/quant ~15–75 USD
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Demonstration projects are therefore required to
examine the acceptability and utility of HCV self-testing
(using either capillary or oral fluid) in high risk popula-
tions or in remote settings, but will first require develop-
ment of validated self-testing protocols for use with the
OraQuick assay. These projects might also examine the
strategies to enhance linkage to HCV RNA following a
positive self-test, particularly for high risk stigmatised
groups with poor access to health services (e.g. MSM,
PWIDs) [34, 35]. If operational research proves the utility
of HCV ST as approach to improve uptake of HCV
screening this might prompt the development of a broader
range of products, with associated cost reductions.
Combination integrated multi-disease tests
As HIV-infected persons continue to live longer due to
increased uptake of anti-retroviral therapies, liver disease
has emerged as a leading cause of morbidity and mortality
in persons co-infected with HBV or HCV. Two recent sys-
tematic reviews and meta-analyses highlight the overlap-
ping epidemics of HIV-HBV and HIV-HCV co-infection
[36, 37]. As twin epidemics in key populations, combin-
ation integrated multi-disease blood or oral based assays
that allow for integrated testing of HIV, HBV and HCV
using a single sample would improve the efficiency of
screening programmes. While not yet fully validated, pre-
liminary results appear promising. Fisher and colleagues
examined the sensitivity and specificity of different multi-
plex POC tests including MedMira rapid antibody test
(whole blood; HIV/ HCV, HBV/HIV/HCV), Chembio
(whole blood, oral specimens; HCV, HIV/HCV, HIV/
HCV/Syphilis), OraSure (whole blood; HCV) [37]. Table 4
summarises the key findings which demonstrated that the
OraSure and Chembio blood tests (including those multi-
plexed with HIV and syphilis) have good performance
characteristics.
A further innovation in HCV serology is a combin-
ation RDT for the simultaneous detection of anti-HCV
and core antigen, allowing for early detection of recent
HCV infection. The HCV core Ag assay has shown to be
as effective as NAT in detecting HCV infection, and
about 6–7 weeks earlier than third generation anti-HCV
assays [38, 39]. The fourth generation Ab-Ag assays are
based on the concurrent detection of core Ag and anti-
HCV and become positive as early as the HCV RNA
assay. This can improve diagnosis of acute hepatitis C
infection, especially in high-risk group populations such
as PWID [40, 41]. In HIV/HCV co-infected patients the
HCV seroconversion if often delayed with the conse-
quence that a conventional anti-HCV screening test fails
to react. The development of new RDTs combining the
simultaneous detection of anti-HCV and core antigen
may also improve detection of hepatitis C infections
among HIV infected persons.
Integrated multidisease testing platforms (centralised and
decentralised)
In addition to the use of multidisease combo RDTs,
several laboratory molecular platforms allow for use of
several disease-specific assays on the same platform. This
applies both to platforms designed for high-throughput
central laboratories as well as “near patient” technologies
deployed closer to patients in lower level health facilities.
The legacy of vertical disease programmes is that many
laboratories have polyvalent platforms used only by the
disease programme that procured it. In addition to the fre-
quent underutilization of the platform, this has also re-
sulted in parallel systems operating for different diseases
in the same laboratory in terms of procurement, sample
workflow, infrastructure and even staff salaries.
The integration of multiple assays on the same plat-
forms has numerous benefits. The same sample referral
system can be used across diseases and improve efficien-
cies in sample workflow. End users can be trained on
multi-disease testing, improving their expertise and ex-
perience in strengthening the quality of testing across
diseases. Inventory management, procurement and sup-
ply chain will improve and eliminate redundancies.
Lastly, the use of multiple assays on the same platform
will increase volume of tests from a single manufacturer
and may be used in price negotiations to achieve bun-
dled prices across diseases.
Sharing the same laboratory platform/instrument across
different diseases makes strategic sense, but will require
substantial re-organisation of laboratory processes, human
resources and cost centres. In many LMICs, this will
Table 4 Performance of HIV/HBV/HCV multiplex POC tests [38]
Company Specimen Sensitivity
(95% CI)
Specificity
(95% CI)
OraSure HCV Antibody Test 92.7% (88.8%–96.5%) 99.8% (99.4%–100%)
Chembio HCV Screen 92.1% (87.7%–96.4%) 99.2% (98.6%–99.9%)
HIV-HCV Assay 91.5% (87.2%–95.7%) 99.4% (98.8%–99.9%)
HIV-HCV-Syphilis 92.3% (88.4%–96.2%) 99.3% (98.8%–99.9%)
MedMira HIV/HCV 79.1% (72.6%–85.5%) 100%
HIV/HCV/HBV 81.5% (75.2%–87.8%) 100%
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require active collaboration between different national dis-
ease programmes and public health laboratory services. A
recent WHO technical update provided a strategic over-
view of key implementation considerations for diagnostic
integration [42]. This document highlights that a country-
led and country-coordinated collaborative process is es-
sential to achieve integration, and that this should be a
priority for both those countries that already have oper-
ational multidisease testing devices, as well as those con-
sidering their introduction. One key aspect in the
selection of polyvalent platforms and selecting sites for de-
ployment is clear mapping of all health facilities based on
the catchment area, target patient populations across
diseases and anticipated testing volumes. Donors and
manufacturers also need to recognise and support the
added value of platform sharing towards health system
strengthening as well as more predictable reagent fore-
casting. All the platforms listed in Table 3 offer a broad
menu of molecular assays covering multiple infectious dis-
eases such as HIV, tuberculosis, viral hepatitis, STIs and
respiratory tract infections. Pilot demonstration projects
on assay integration into polyvalent platforms are needed
to assess the capacity of the system (i.e. logistics and hu-
man resources) to achieve sharing across disease pro-
grammes. These projects can also help define placement
criteria and inform implementation at country level.
New technologies
Point-of-care (POC) molecular technologies (quantitative
and qualitative)
NAT assays can now be performed on POC devices out-
side of laboratory settings. Point-of-care testing or near
patient testing is defined as medical diagnostic testing
at or near the point of care—that is, at the time and
place of patient care. The delivery of health care at the
most peripheral levels of the health system has played a
critical role in antiretroviral treatment (ART) scale-up
and access to TB care and treatment and is now being
progressively applied to HCV and HBV testing and
treatment scale-up [6, 43, 44]. While existing HIV viral
load tests require laboratory infrastructure and highly
trained technicians, POC devices can be battery oper-
ated, are easy to use as they require minimal hands on
time (sample in-answer out), results are available in less
than 2 h (shorter turnaround time) and reagents can be
stored at ambient temperature. Most come with data
transmission capability for automated surveillance, and
the opportunity to link in quality assurance and supply
chain software to avoid stock-outs [45]. POC qualitative
assays are used widely for diagnosis of TB and quantitative
assays for monitoring of ART treatment response by
measuring HIV viral load. In Mozambique, it was demon-
strated that POC HIV viral load testing is operationally
feasible at the primary health care level [46]. Similarly, the
roll-out of the POC TB assay has demonstrated that mo-
lecular diagnostics can produce rapid diagnosis and treat-
ment initiation [47]. Such innovative technologies for HIV
have been promoted as a means to reach the third 90 (un-
detectable viral load) of the UNAIDS/WHO 90–90-90 tar-
gets for HIV elimination, but also provide opportunities to
test for other diseases [48–50].
Experience with use of POC virological diagnosis in
viral hepatitis is largely confined to evaluation of HCV
RNA, where the major potential value is to allow same
day or next day confirmation of viraemic infection and
so prompt initiation of treatment. The GeneXpert HCV
viral load manufactured by Cepheid is currently the only
WHO pre-qualified (PQ) molecular test for viral hepa-
titis and was included on the in vitro diagnostic (IVD)
product list in April 2017. This complements the exist-
ing WHO PQ approval for the GeneXpert TB and HIV
viral load instruments [51]. The major potential value of
POC for HCV viral load is to allow potentially same day
or next day confirmation of viraemic infection and so
prompt initiation of treatment, but will also be import-
ant for confirmation of viral cure. It takes around
110 minutes for a result, and depending on the size of
instrument (cartridge capacity) may run generally be-
tween 8 to 20 samples per day. The company has also
developed a combo cartridge containing HIV-1 viral load
(CE-IVD) and HBV viral load (for research use only).
At present there is only one HCV NAT qualitative
product that it is close to commercialization. The
Genedrive®, developed by the UK-based biotechnology
company Epistem Ltd., is highly-portable and uses end-
point PCR-based detection, and is expected to achieve
European CE marking by the end of 2017. Sample prep-
aration includes several manual steps that can hamper
proper execution when performed by users with minimal
laboratory training. Two HCV NAT qualitative products
are also close to market approval. The GeneXpert Omni
(Cepheid Inc.) is expected to be available in emerging
markets in the third quarter of 2017 [52]. This device le-
verages on Cepheid existing cartridge technology with
the objective of expanding access to clinical molecular
diagnostic testing in decentralised locations. The com-
pany Molbio (Molbio Diagnostics Pvt. Ltd., India) aims
to launch the Truenat HCV viral load assays in 2018.
Truenat HCV is a chip based PCR test that runs on
Molbio’s Truelab Uno Dx microPCR device, and uses
the Trueprep Auto Sample station that automatically
prepares the sample in approximately 20 min.
There is an evolving pipeline of other POC technologies
for assessment of HCV viral load, and UNITAID will pub-
lish an updated landscape report on HCV diagnostics by
the end of 2017 [14]. The biotechnology industry remains
very active in developing NAT POC instruments with new
functionalities. The small size of these devices makes them
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suitable for very small laboratories and/or mobile clinics,
while features such as modularity and connectivity allow
flexible uses and deployment options.
Use of HCVcAg as alternative to NAT
The HCV core antigen test was developed as an alterna-
tive to NAT, as access to and affordability of HCV con-
firmatory RNA NAT assays remains a challenge in
resource-limited settings. The availability of a highly ac-
curate immunoassay that can perform quantitative HCV
cAg assays would be valuable in settings where NAT or
near-NAT is not accessible, especially if it can reduce
the cost of monitoring. HCVcAg assays may also be use-
ful as a one-step screening test (as for NAT HCV RNA)
in high prevalence populations or settings because
HCVcAg appears earlier than HCV antibodies, and has
a high specificity, so does not require any further con-
firmatory testing. Major advantages of HCVcAg assay
in comparison to HCV RNA assays are cost per test,
turnaround time and the random access to a platform
that does not require specimen batching. However, the
most widely used HCVcAg assay, a two-step chemilu-
minescent microparticle immunoassay (ARCHITECT
HCV Ag), requires a floor-standing immunoassay
analyser (ARCHITECT-i2000R, Abbott Diagnostics,
Illinois, USA. A systematic review concluded that a
well-performing HCVcAg test can have a similar diag-
nostic accuracy compared to NAT when the viral load
is greater than 3000 IU/mL [13]. More recent data
shows high sensitivity and specificity of HCVcAg when
compared to HCV RNA for detection of viremia both
before treatment and after treatment [53, 54]. The
quantification of HCVcAg as a one-step approach in
diagnosing chronic hepatitis C infection has also been
evaluated in Cameroon and showed 95.7% sensitivity
and 99.7% specificity, that was similar among those
with HIV or HBV- coinfection [55]. Operational re-
search studies are now needed to assess the relative
utility, cost-effectiveness and challenges in use of
HCVcAg compared to HCV RNA NAT in the context
of national hepatitis programmes. The development of
a highly sensitive POC platform that meets the require-
ments of the target product profile for a test of
viraemia developed by FIND and WHO may also prove
a more cost-effective option than NAT POC tests [56].
Health system improvements
Integrated testing and decentralisation
Integration of viral hepatitis testing and care with other
health services, and decentralization to lower level health
facilities and task-shifting are all health system approaches
that may improve the accessibility of hepatitis testing and
linkage to care. The availability of simplified but highly ef-
fective DAA treatment regimens means that routine
management of hepatitis C treatment can increasingly be
provided outside of specialized centres and tertiary institu-
tions, so the number of patients accessing viral hepatitis
services also increased. The delivery of care and treatment
of HCV infected PWID by primary health care providers
was shown to be as safe and effective as that provided by
specialists [57, 58]. Viral hepatitis services and particularly
hepatitis B management in sub-Saharan Africa may also
be integrated into the existing infrastructure of HIV pro-
grammes for testing, care and treatment.
Other recommended interventions to promote uptake
of hepatitis testing and linkage to care include peer and
lay health worker support in community-based settings,
clinician reminders to offer testing, and testing as part of
integrated services, alongside the use of different media
strategies to promote awareness about hepatitis in the
general population [6, 15, 59, 60].
Connectivity
Accurate and timely diagnostic test information is
critical for the proper functioning of the diagnostic and
treatment cascade including patient management, epi-
demiological surveillance, quality assurance, laboratory
operations, and technical support. An accessible stan-
dardized database that enables integration with labora-
tory information systems, electronic health records, and
health programme databases can allow diagnostics to
meet these broad-ranging needs. Connectivity has become
a default requirement for TB diagnostics and according to
the WHO Framework of indicators and targets for labora-
tory strengthening under the End TB Strategy, all sites
that use WHO-recommended rapid diagnostics should be
transmitting results electronically to clinicians and to in-
formation management systems using data connectivity
solutions no later than 2020 (Indicator 4) [61].
Connectivity solutions that link POC testing sites to a
central laboratory also allow control programmes to
track trends and assess the impact of special interven-
tions. Many new molecular POC devices have data
transmission capabilities via Wi-Fi or cellular networks,
creating automated real-time surveillance systems [62].
For RDTs, readers or mobile phones can be used to
standardize test interpretation, eliminating subjectivity.
A microfluidic based serology test for HIV and syphilis
antibody detection has been designed to be powered and
read by a smart phone, thus automating data transmis-
sion to a central database [63]. Connectivity solutions
can also improve the turn-around time of external quality
assessment result submissions and allow corrective ac-
tions to be provided immediately [64]. It is essential that
connectivity solutions address both the current and future
needs of viral hepatitis programmes. These needs can in-
clude enhanced technical features and functions, integra-
tion with other systems or be financial in nature. It is also
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essential that innovative solutions are appropriately imple-
mented to optimise utilization and resource use.
Supply chain and sample management
Supply chain management is one of the most challen-
ging problems in health care delivery in the developing
world [65]. As testing coverage increases with POC diag-
nostics reaching more remote areas, supply chain man-
agement will also become more decentralized, putting
additional stresses on already fragile health systems suf-
fering from a shortage of health care personnel and fre-
quent stock outs. Innovative connectivity solutions can
support the management of decentralized testing. The
availability of connectivity solutions that can be installed
on both high-throughput and POC devices may improve
optimization of central supply chain and procurement
mechanisms, by linking consumption data across mul-
tiple testing sites and for multiple diseases [64]. Similar
solutions could be adopted to improve communication
between peripheral clinics and central testing laboratories
to optimize sample workflow [66]. For example, informa-
tion could be transmitted to the testing laboratory as soon
as a test is registered at the clinic. Realtime information
on volumes expected would allow the testing laboratory to
better plan their workflow.
Conclusions and research agenda in viral hepatitis
diagnostics
Innovations in testing and sampling approaches have the
potential to increase access to testing and reduce the
large burden of undiagnosed infection. These include
the use of non-invasive sampling with oral fluid and po-
tential self-testing among marginalized populations, al-
though linkage to care will still represent a challenge.
Multiplex platform molecular technologies will allow
programmes to leverage investments in existing plat-
forms for HIV or TB and increase access to testing for
viral hepatitis. Additional areas to ensure successful
adoption of new technologies include strengthening la-
boratory support systems, such as sample transport,
quality management, and training.
There are well recognized research gaps in viral hepa-
titis diagnostics and many of these were highlighted
throughout the WHO testing guidelines for chronic
hepatitis B and C. These include both development of
new innovative technologies, and high quality demon-
stration projects and implementation science to evaluate
performance, impact and costs. In 2016 UNITAID
awarded FIND a grant to address some of the challenges
and operational questions relating to HCV diagnosis,
working in collaboration with WHO and other partners.
The key project goal is to advance progress towards the
WHO elimination targets for HCV by 2030: 90% re-
duction in incidence; 65% reduction in mortality; and
80% of patients receiving treatment [5]. The key out-
come is to support the updating of WHO normative
guidelines on viral hepatitis testing as well as national
policies that will support scale-up of HCV care and
treatment. Specific activities and deliverables are sum-
marized in Table 5 and include: 1) accelerating the de-
velopment of new, simpler, quality-assured HCV tests
and making them available in LMICs; 2) establishing
innovative approaches for screening and treatment in
HCV infected patients in 6 countries (Cameroon,
Georgia, India, Myanmar, Viet Nam and Malaysia); 3)
implementing a cost reduction strategy for diagnosis;
and 4) providing the evidence to drive scale up, transi-
tion and sustainability.
Table 5 Areas of activity and key deliverables of FIND-UNITAID project
Areas of activity Key deliverables
Enable platform polyvalence and HCV/HIV integration through supporting
DBS protocol development, regulatory approval and policy change
- Evaluation of DBS sampling for centralized EIA and RNA assays
- Use of existing HIV lab infrastructure for introducing HCV testing
- Demonstrate service delivery advantages of one step sampling
(EIA/ RNA) using DBS
Expand use of HCV core antigen assays - Compare cAg against gold standard as test of cure using current
lab-based technology
- Evaluate feasibility, cost, cost-effectiveness and impact of cAg assay
as one testing approach in high prevalence populations
- Accelerate development of POC cAg devices
Enable decentralization of HCV services - Integration of HCV/TB/HIV assays in decentralized settings
- Demonstrate feasibility of HCV testing and treatment in different
decentralized settings
- Costing of different testing/ treatment pathways across countries
and sites
- Evaluate acceptability and cost-effectiveness of finger stick blood
sample collection
- Accelerate development of POC molecular devices
Increase access to quality-assured HCV RDTs - Piloting quality-assured RDTs using capillary blood in high risk groups
- Assess market and feasibility of HCV ST and/or combo test among
different populations
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